Home
Overview/Our mission
News and Events
Stock Quote
About us
At a glance
Our values
Management team
Board of Directors
Scientific Advisors
Cell Therapy Scientific Advisory Board
Glioblastoma Scientific Advisory Board
Science
NK Cell Derived Allogeneic Therapies
CHM 0201 (CORE-NK Platform)
CHM 0301 (Next Generation CORE-NK Platform)
CHM 1301 (CLTX CAR-NK)
CHM 2301 (CDH17 CAR-NK)
CHM 3301 (Undisclosed CAR-NK)
T Cell Derived Autologous Therapies
CHM 1101 (CLTX CAR T)
CHM 2101 (CDH17 CAR T)
Collaborations
About Cell Therapy
Pipeline
Overview
Clinical Trials
CHM 1101 (CLTX CAR T)
CHM 0201 (CORE-NK Platform)
Abstracts and Publications
News and Events
Press releases
Events and presentations
Media Coverage
Media Resources
INVESTOR HUB
Careers
Menu
Home
Overview/Our mission
News and Events
Stock Quote
About us
At a glance
Our values
Management team
Board of Directors
Scientific Advisors
Cell Therapy Scientific Advisory Board
Glioblastoma Scientific Advisory Board
Science
NK Cell Derived Allogeneic Therapies
CHM 0201 (CORE-NK Platform)
CHM 0301 (Next Generation CORE-NK Platform)
CHM 1301 (CLTX CAR-NK)
CHM 2301 (CDH17 CAR-NK)
CHM 3301 (Undisclosed CAR-NK)
T Cell Derived Autologous Therapies
CHM 1101 (CLTX CAR T)
CHM 2101 (CDH17 CAR T)
Collaborations
About Cell Therapy
Pipeline
Overview
Clinical Trials
CHM 1101 (CLTX CAR T)
CHM 0201 (CORE-NK Platform)
Abstracts and Publications
News and Events
Press releases
Events and presentations
Media Coverage
Media Resources
INVESTOR HUB
Careers
Linkedin-in
Youtube
Twitter
Envelope
January 2021
Analyst Coverage
Edison Research Report: Scorpion venom CAR T stalking GBM
Next
Edison Research Report: Acquiring a First in Class Novel CAR T for Solid Tumous
Next
Share on facebook
Share on twitter
Share on linkedin
